Arcus Biosciences announces results from Part 1 of ARC-10 trial

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus zimberelimab or chemotherapy in patients with front-line locally advanced or metastatic squamous or non-squamous non-small cell lung cancer, or NSCLC with PD-L1 tumor proportion score, or TPS, of 50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. This study was conducted in partnership with Gilead Sciences (GILD). These results will be presented on November 8 in a late-breaking poster session at the Society for Immunotherapy of Cancer, or SITC, 2024 annual meeting. At the time of data cutoff, 98 patients were randomized and 95 received treatment in Part 1 of the study. The median follow-up was 24.5 months, and as of the DCO, 22 patients remained on treatment. Patient baseline demographics were generally balanced across the arms, with a slight imbalance of more patients with adenocarcinoma, ECOG status 0, and brain metastasis favoring the chemotherapy arm. A summary of efficacy results is below. DZ and Z were generally well tolerated with no new safety concerns at the time of DCO. Treatment-related adverse events, or TRAEs, leading to treatment discontinuation were higher for chemotherapy than for DZ and Z. Infusion-related reactions were low. Grade 3 TRAEs were higher for chemotherapy than for DZ or Z. TRAEs leading to death were lower for DZ vs Z.